The current “four-pillar therapy” for HF includes ACE inhibitors (ACEi) or angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). This evidence concerns the gene NR3C2 and hydrops fetalis.